Table 2.
Shared gene profile (N = 60) | Number of patients | Represented histologies in liquid biopsy |
---|---|---|
TP53 | 19 | Hepatocellular carcinoma (N = 7), colorectal adenocarcinoma (N = 4), pancreatic ductal adenocarcinoma (N=3), esophageal adenocarcinoma (N = 2), cholangiocarcinoma (N = 1), appendix adenocarcinoma (N = 1), gallbladder carcinoma (N = 1) |
KRAS | 10 | Colorectal adenocarcinoma (N=4), pancreatic ductal adenocarcinoma (N=2), appendix adenocarcinoma (N=2), cholangiocarcinoma (N=1), pancreatic neuroendocrine tumor (N=1) |
KRAS, TP53 | 9 | Colorectal adenocarcinoma (N=5), pancreatic ductal adenocarcinoma (N=2), esophageal adenocarcinoma (N=1), GIST (N=1) |
TP53, KRAS, MYC | 4 | Appendix adenocarcinoma (N=1), colorectal adenocarcinoma (N=1), gastric adenocarcinoma (N=1), pancreatic ductal adenocarcinoma (N=1) |
RAF1 | 2 | Duodenum adenocarcinoma (N=1), gastric adenocarcinoma (N=1) |
APC | 2 | Colorectal adenocarcinoma (N=2) |
GNAS | 2 | Appendix adenocarcinoma (N=1), colorectal adenocarcinoma (N=1) |
CTNNB1 | 2 | Hepatocellular carcinoma (N=2) |
KRAS, MYC | 2 | Colorectal adenocarcinoma (N=1), pancreatic ductal adenocarcinoma (N=1) |
CTNNB1, TP53 | 2 | Hepatocellular carcinoma (N=2) |
APC, TP53 | 2 | Colorectal adenocarcinoma (N=2) |
PIK3CA, TP53 | 2 | Colorectal adenocarcinoma (N=1), hepatocellular carcinoma (N=1) |
APC, KRAS, TP53 | 2 | Colorectal adenocarcinoma (N=2) |
Shared molecular alteration profile (N = 6) | Number of patients | Represented histologies in liquid biopsy |
KRAS G12D | 2 | Pancreatic ductal adenocarcinoma (N=1), colorectal adenocarcinoma (N=1) |
GNAS R201H | 2 | Appendix adenocarcinoma (N=1), colorectal adenocarcinoma (N=1) |
KRAS G12V | 2 | Appendix adenocarcinoma (N=2) |
Shared molecular alteration profile (N = 2) | Number of patients | Represented histologies in tissue biopsy |
KRAS G12R | 2 | Pancreatic ductal adenocarcinoma (N=1), colorectal adenocarcinoma (N=1) |
Abbreviations: VUS = variant of unknown significance, GIST = gastrointestinal stromal tumor
Patients sharing gene profiles had the same sets of genes altered, while shared alteration profiles were patients who had the same sets of specific alterations at the same gene.